Key Drivers
- Strong liquidity
- No revenue
- Ongoing cash burn
AIAI Summary
SION should now be viewed less as a financing-risk biotech and more as a well-funded, catalyst-driven cystic fibrosis story whose upside depends almost entirely on near-term SION-719 and SION-451 data, because the strong cash runway reduces dilution risk but any weak readout would quickly reset the binary valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •No revenue
- •Ongoing cash burn
SION has very strong liquidity and minimal leverage, but its lack of revenue, persistent losses, and ongoing cash burn make the investment case dependent on balance-sheet strength rather than operating performance.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Range resistance
- •Volatile pullbacks
SION's last month trend is technically constructive, with a series of higher lows and a rebound to a new closing high, but it needs a clean break above $44.00 while $41.00–$41.64 remains key support.
Sharp early drop and a failed hold on 2026-07-01 highlight volatility
Sentiment & News
Key News Insights:
- •Summer readouts
- •Cash runway
- •CFTR boost
Sionna Therapeutics is advancing its NBD1-stabilization cystic fibrosis pipeline toward key summer 2026 clinical readouts, while a $289.9M cash runway reduces near-term financing risk.
This is a modestly positive setup for SION, as funding visibility and upcoming pivotal data keep the stock focused on clinical execution and potential value creation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings